Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Multiple myeloma (MM) is a heterogeneous plasma cell malignancy.
• High-risk MM patients exhibit rapid progression and frequent relapse despite current therapies.
• Gene expression profile (GEP)-defined high risk is a significant predictor of relapse in MM.

Purpose of the Study:

• To evaluate a novel treatment strategy in the Total Therapy 5 trial for high-risk multiple myeloma.
• To assess the efficacy of reduced drug intensity with shorter intervals to prevent inter-course relapse.
• To determine the impact of this regimen on early mortality, relapse rates, progression-free survival (PFS), and overall survival (OS).

Main Methods:

• The Total Therapy 5 trial investigated a modified dosing schedule for high-risk multiple myeloma patients.
• This approach involved less intense drug dosing with shorter intervals between treatment courses.
• Outcomes including early mortality, relapse, PFS, and OS were analyzed.

Main Results:

• The tested regimen significantly reduced early mortality and the rate of early relapse.
• However, the strategy did not lead to an improvement in progression-free survival (PFS).
• Overall survival (OS) was also not improved, with relapses occurring early during the maintenance phase.

Conclusions:

• The modified dosing strategy in the Total Therapy 5 trial effectively reduced early mortality and relapse in high-risk multiple myeloma.
• Despite these benefits, the regimen failed to improve progression-free survival and overall survival.
• Further research is needed to optimize treatment strategies for preventing late-stage relapse in high-risk multiple myeloma.